Our results in numbers
A US-headquartered biotech was developing a novel molecule in a pain indication.
Placebo-controlled pivotal studies met primary endpoints, consistent with FDA expectations, and the product was on track for NDA submission.
However, European payers expect evidence of value versus currently used therapies, so our client needed AESARA’s European access experts to inform their European access strategy
Value evidence and Access strategy
A US-headquartered biotech was developing a novel molecule in a pain indication. Placebo-controlled pivotal studies met primary endpoints, consistent with FDA…
RWE Strategy implementation
A request from a top-10 joint venture development alliance asked AESARA to develop a proactive real-world evidence (RWE) strategy. The purpose of the initiative is to facilitate the cross-functional…
Required immediate resourcing to support US market entry for uterine fibroid product. AESARA was asked to dedicate experienced value and access…
The HEOR team at a major pharmaceutical company was evaluating their life-cycle management strategy in a competitive oncology field and needed…
Virtual AD board
A top 10 global pharma with an innovative Cell Therapy pipeline, our client needed to be able to work with target health care systems and understand how to…
Change before Change
We are forward thinking and driven by the impact you need